Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13240* | 2021 |
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3084 | 2013 |
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The lancet oncology 18 (9), 1182-1191, 2017 | 2568 | 2017 |
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 1919 | 2018 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ... New England Journal of Medicine 372 (20), 1909-1919, 2015 | 1409 | 2015 |
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer AF Sobrero, J Maurel, L Fehrenbacher, W Scheithauer, YA Abubakr, ... Journal of clinical oncology 26 (14), 2311-2319, 2008 | 1196 | 2008 |
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase D Salonga, KD Danenberg, M Johnson, R Metzger, S Groshen, ... Clinical Cancer Research 6 (4), 1322-1327, 2000 | 1116 | 2000 |
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy R Tokunaga, WU Zhang, M Naseem, A Puccini, MD Berger, S Soni, ... Cancer treatment reviews 63, 40-47, 2018 | 1041 | 2018 |
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer E Van Cutsem, HJ Lenz, CH Köhne, V Heinemann, S Tejpar, I Melezínek, ... Journal of clinical oncology 33 (7), 692-700, 2015 | 925 | 2015 |
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors PG Johnston, HJ Lenz, CG Leichman, KD Danenberg, CJ Allegra, ... Cancer research 55 (7), 1407-1412, 1995 | 904 | 1995 |
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six … D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ... Annals of oncology 28 (8), 1713-1729, 2017 | 884 | 2017 |
ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy Y Shirota, J Stoehlmacher, J Brabender, YP Xiong, H Uetake, ... Journal of Clinical Oncology 19 (23), 4298-4304, 2001 | 858 | 2001 |
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 833 | 2017 |
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer MM Pomerantz, N Ahmadiyeh, L Jia, P Herman, MP Verzi, ... Nature genetics 41 (8), 882-884, 2009 | 789 | 2009 |
Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ... JAMA oncology 3 (2), 194-201, 2017 | 783 | 2017 |
Activity of sunitinib in patients with advanced neuroendocrine tumors MH Kulke, HJ Lenz, NJ Meropol, J Posey, DP Ryan, J Picus, E Bergsland, ... Journal of Clinical Oncology 26 (20), 3403-3410, 2008 | 756 | 2008 |
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy ST Pullarkat, J Stoehlmacher, V Ghaderi, YP Xiong, SA Ingles, A Sherrod, ... The pharmacogenomics journal 1 (1), 65-70, 2001 | 729 | 2001 |
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil … R Metzger, CG Leichman, KD Danenberg, PV Danenberg, HJ Lenz, ... Journal of Clinical Oncology 16 (1), 309-316, 1998 | 689 | 1998 |
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret … AA Garcia, H Hirte, G Fleming, D Yang, DD Tsao-Wei, L Roman, ... Journal of Clinical Oncology 26 (1), 76-82, 2008 | 681 | 2008 |
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ... Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014 | 645 | 2014 |